Business Description
Karyopharm Therapeutics Inc
NAICS : 325412
SIC : 5999
ISIN : US48576U1060
Total Employee Number:
228Description
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.39 | |||||
Equity-to-Asset | -2.02 | |||||
Debt-to-Equity | -0.87 | |||||
Debt-to-EBITDA | -1.57 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -21.21 | |||||
Beneish M-Score | -5.57 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -22.6 | |||||
3-Year EBITDA Growth Rate | 18.7 | |||||
3-Year EPS without NRI Growth Rate | 23.8 | |||||
3-Year FCF Growth Rate | 36.9 | |||||
3-Year Book Growth Rate | -93.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 52.63 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 15.46 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 26.96 | |||||
9-Day RSI | 30.83 | |||||
14-Day RSI | 35.08 | |||||
3-1 Month Momentum % | 13.42 | |||||
6-1 Month Momentum % | 53.64 | |||||
12-1 Month Momentum % | 164.06 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.08 | |||||
Quick Ratio | 1.05 | |||||
Cash Ratio | 0.77 | |||||
Days Inventory | 260.23 | |||||
Days Sales Outstanding | 72.26 | |||||
Days Payable | 269.72 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -34.4 | |||||
Shareholder Yield % | -43.25 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 96.03 | |||||
Operating Margin % | -55.73 | |||||
Net Margin % | -129.02 | |||||
EBITDA Margin % | -97.49 | |||||
FCF Margin % | -39.25 | |||||
OCF Margin % | -39.25 | |||||
ROA % | -171.43 | |||||
ROIC % | -244.18 | |||||
3-Year ROIIC % | -947.64 | |||||
ROC (Joel Greenblatt) % | -2941.88 | |||||
ROCE % | -893.72 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.5 | |||||
EV-to-EBIT | -2.04 | |||||
EV-to-EBITDA | -2.04 | |||||
EV-to-Revenue | 1.99 | |||||
EV-to-Forward-Revenue | 2.04 | |||||
EV-to-FCF | -5.12 | |||||
Price-to-GF-Value | 1.19 | |||||
Price-to-Median-PS-Value | 0.08 | |||||
Earnings Yield (Greenblatt) % | -49.09 | |||||
FCF Yield % | -36.76 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Karyopharm Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 129.844 | ||
| EPS (TTM) (€) | -12.949 | ||
| Beta | 3.4194 | ||
| 3-Year Sharpe Ratio | 0.12 | ||
| 3-Year Sortino Ratio | 0.2 | ||
| Volatility % | 118.81 | ||
| 14-Day RSI | 35.08 | ||
| 14-Day ATR (€) | 0.666296 | ||
| 20-Day SMA (€) | 8.1825 | ||
| 12-1 Month Momentum % | 164.06 | ||
| 52-Week Range (€) | 3.1 - 9.4 | ||
| Shares Outstanding (Mil) | 22.66 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Karyopharm Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Karyopharm Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-03 08:00 | In 103 days | ||
| Third quarter earnings results for 2026 | 2026-11-03 | In 102 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-11 08:00 | In 19 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | In 18 days | ||
| Guidance call for 2026 | 2026-06-04 08:10 | 7.65 (-1.92%) | ||
| Guidance call for 2026 | 2026-06-02 14:00 | 8.40 (+8.39%) | ||
| General meeting for 2026 | 2026-05-21 09:00 | 6.75 (+5.47%) | ||
| Guidance call for 2026 | 2026-05-19 15:35 | 6.15 (-4.65%) | ||
| First quarter earnings conference call for 2026 | 2026-05-14 08:00 | 7.50 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 7.50 (+0.00%) |
Show
Entries
Karyopharm Therapeutics Inc Frequently Asked Questions
What is Karyopharm Therapeutics Inc(STU:25K0)'s stock price today?
The current price of STU:25K0 is €6.15. The 52 week high of STU:25K0 is €9.40 and 52 week low is €3.10.
When is next earnings date of Karyopharm Therapeutics Inc(STU:25K0)?
The next earnings date of Karyopharm Therapeutics Inc(STU:25K0) is 2026-08-11 Est..
Does Karyopharm Therapeutics Inc(STU:25K0) pay dividends? If so, how much?
Karyopharm Therapeutics Inc(STU:25K0) does not pay dividend.
Press Release
Articles on Karyopharm Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers